NinesAI

by Sirona Medical  · Based in United States → — Cloud-Native Radiology Software
Neurology Oncology Radiology

Subscription-based
Regulatory Status Disclosed

Overview

NinesAI, developed by Nines, was an artificial intelligence tool designed to assist radiologists in the interpretation and prioritization of medical images. Its core functionalities included the automated radiological review of CT Head images for the possible presence of time-critical indications such as intracranial hemorrhage and mass effect, aiding radiologists in triaging cases. Additionally, Nines developed NinesMeasure, an AI-powered tool for semi-automatic measurement of lung nodules on adult thoracic CT images, aimed at accelerating diagnoses of certain respiratory diseases.

These AI algorithms are now integrated into Sirona Medical’s cloud-native radiology operating system (RadOS), which unifies radiology IT applications such as worklist, viewer, reporter, and AI into a single, streamlined platform. The original premise of NinesAI being a ‘physician directory’ tool is not supported by the available information; its focus was on enhancing diagnostic radiology workflows.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered triage for emergent conditions (intracranial hemorrhage, mass effect)
  • Automated lung nodule measurement and analysis
  • Enhanced radiologist workflow efficiency and prioritization
  • Integration into radiology operating systems (now Sirona's RadOS)
  • Machine learning algorithms for medical image analysis
  • Cloud-native architecture (via Sirona Medical's RadOS)
  • Unified worklist, viewer, and reporting (via Sirona Medical's RadOS)
  • Supports faster diagnosis of critical conditions

Use Cases

  • Prioritizing critical radiology cases for expedited review
  • Expediting diagnosis of life-threatening neurological conditions
  • Quantitative analysis and tracking of pulmonary nodules
  • Improving radiologist efficiency and reducing burnout
  • Integration into teleradiology practices and hospital networks
  • Streamlining radiology IT infrastructure and workflows

What Physicians Need to Know

Stroke Detection Speed
NinesAI Emergent Triage, acquired by Sirona Medical, can notify radiologists of potential life-threatening findings, such as intracranial hemorrhage, approximately 15 seconds after a scan is completed.
Brain MRI/CT Analysis
Sirona Medical acquired Nines' AI capabilities, including its clinical data pipeline and machine learning engines, which are integrated into its RadOS platform. NinesAI Emergent Triage provides automated review of head CT exams for intracranial hemorrhage and mass effect. The RadOS platform is designed to unify various radiology IT applications, including viewing, and is built to power a new generation of AI that is broad, speech-driven, pixel-powered, and real-time. The Sirona Reporter ingests DICOM pixel data natively, allowing AI to work directly from images while the radiologist reads.
Large Vessel Occlusion Detection
NinesAI Emergent Triage is an FDA-cleared set of AI-powered algorithms that triages time-critical, life-threatening indications of intracranial hemorrhage and mass effect. While not explicitly stated for NinesAI, other AI stroke detection systems achieve 90-95% accuracy for identifying large vessel occlusions (LVOs) and intracerebral hemorrhages. These systems can analyze CT scans in 1-6 minutes, significantly faster than traditional radiology workflows. Some AI tools for LVO detection have shown high specificity and moderately high sensitivity.
Triage Prioritization Speed
NinesAI Emergent Triage is an FDA-cleared AI-powered algorithm that triages time-critical, life-threatening indications of intracranial hemorrhage and mass effect. Radiologists using NinesAI can be notified of a potential life-threatening finding approximately 15 seconds after the scan is completed.
Physician Tip

NinesAI Emergent Triage, integrated into Sirona's RadOS platform, offers rapid detection of critical neurological conditions like intracranial hemorrhage and mass effect on head CTs, with notifications in approximately 15 seconds. This speed can significantly aid in prioritizing urgent cases. The platform's ability to unify viewing, reporting, and AI tools into a single cloud-native system can streamline workflow and reduce the need for multiple applications. The pixel-powered reporting feature allows AI to work directly from DICOM images, providing real-time assistance and drafting impressions, which can enhance efficiency and accuracy in reporting. While NinesAI focuses on emergent triage, the broader RadOS platform is designed to integrate a growing catalog of FDA-cleared partner algorithms, offering potential for future expansion into other neurological AI applications.

Sirona Medical's RadOS platform is designed as an orchestration layer that routes studies to configured algorithms and brings outputs back into a single reading interface. It integrates Sirona's own AI and FDA-cleared partner algorithms, surfacing results inline with the study. The platform unifies reporting, viewing, PACS, worklist, and AI. Sirona's acquisition of Nines' AI capabilities, including NinesAI Emergent Triage, means these tools are integrated into the RadOS platform. The Sirona Reporter overlays on top of existing PACS using standard DICOM and HL7 interfaces, allowing for a modern reporter with AI while keeping the current PACS. Sirona does not build reimbursable AI but integrates partners who do.

Details

Category Neurology AI, Oncology AI, Radiology & Imaging AI
Pricing Subscription-based
DeploymentCloud-native
Mobile App1
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Oncology, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2020-04-21K193351 510(k)NinesAI

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate NinesAI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for NinesAI.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

NinesAI, developed by Sirona Medical, is primarily focused on radiology. It includes FDA-cleared algorithms like NinesAI Emergent Triage, which analyzes head CT images to identify potential intracranial hemorrhage and mass effect, helping to prioritize critical cases for radiologists. While not directly a neurology-specific tool for diagnosis or treatment planning, its integration into radiology workflows can indirectly benefit neurology by expediting the identification of acute neurological emergencies requiring prompt intervention.
NinesAI Emergent Triage is an FDA-cleared medical device, indicating it has met specific regulatory standards for its intended use in triaging head CT images for intracranial hemorrhage and mass effect. As with any AI tool in healthcare, its use should align with institutional policies, data privacy regulations like HIPAA, and ethical guidelines to ensure patient safety and data security.
Yes, several AI tools are designed specifically for neurology practices. These include AI scribes like DeepCura AI and Freed AI for documentation, clinical decision support systems like MedLink AI and EvidenceMD for complex differentials and evidence-based guidance, and tools for predictive analytics and continuous wearable monitoring. These alternatives address various neurological needs beyond the radiology-focused triage offered by NinesAI.
Specific pricing for NinesAI by Sirona Medical is not publicly disclosed. However, when NinesAI was initially launched by Nines, Inc. (before its acquisition by Sirona Medical), it was offered for free to existing and new customers for a limited period, particularly during the COVID-19 pandemic. For current pricing information, direct inquiry with Sirona Medical would be necessary.
NinesAI's primary limitation for neurologists is its specific focus on radiological triage of acute conditions like intracranial hemorrhage and mass effect from CT scans. It is not designed for comprehensive neurological diagnosis, treatment planning, or long-term patient management. It serves as a tool to aid radiologists in prioritizing emergent cases, rather than directly assisting neurologists with their broader clinical decision-making or documentation needs.
NinesAI's integration is primarily within Sirona Medical's radiology operating system (RadOS), which aims to unify various radiology IT applications. While RadOS seeks to streamline radiology workflows, direct integration with neurology-specific EHR systems for broader neurological patient data management is not explicitly detailed. Its function is to provide AI-powered insights within the imaging workflow, which would then be communicated through standard hospital systems.
In performance testing, NinesAI demonstrated a sensitivity of 0.899 for intracranial hemorrhage and 0.964 for mass effect, with specificities of 0.974 and 0.911, respectively. This indicates a high level of accuracy in identifying these critical conditions on head CT images, aiding in the rapid prioritization of cases for radiologist review.

Related Tools

syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
Neurophet AQUA AD Plus
Neurophet
Neurology AI
Neurophet AQUA AD Plus is an AI-powered brain imaging analysis software that supports the diagnosis, treatment guidance, and monitoring of Alzheimer's disease by analyzing MRI and PET scans.
myosmart trial kit
Otto Bock Healthcare Products GmbH
Neurology AI
The Ottobock MyoSmart Trial Kit assists clinicians in assessing and fitting advanced neurorehabilitation prosthetic and orthotic solutions.
connectgrip. (560X27-1)
Otto Bock Healthcare Products GmbH
Neurology AI
Otto Bock Healthcare Products GmbH offers advanced prosthetic and orthotic solutions, with 'connectgrip' (560X27-1) likely being a component designed for secure and functional connection within these systems, potentially incorporating intelligent features for enhanced user control.
myosmart.cuff (757M20-2)
Otto Bock Healthcare Products GmbH
Lab & Diagnostics
The myosmart.cuff is a medical device by Otto Bock Healthcare Products GmbH designed for objective measurement of muscle tone, primarily for use in neurological rehabilitation.
myosmart. (13E522)
Otto Bock Healthcare Products GmbH
Neurology AI
myosmart.

See all Neurology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-11 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.